FAKTOR-OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 15:35:31 2024-06-07 EDT | ||
| 9.99 EUR | +1.52% |
|
| Current month | +2.25% | ||
| 1 month | +6.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 9.99 | +1.52% |
| 24-06-06 | 9.84 | +4.90% |
| 24-06-05 | 9.38 | -4.96% |
| 24-06-04 | 9.87 | +0.82% |
| 24-06-03 | 9.79 | +0.20% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 03:35 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW9NAT |
| ISIN | DE000SW9NAT5 |
| Date issued | 2024-04-29 |
| Strike | 1,916 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.22 € |
|---|---|
| Lowest since issue | 8.76 € |
| Spread | 0.19 € |
| Spread % | 1.87% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.67%
- Stock Market
- Certificates
- Certificat
